利奈唑胺治疗ICU脓毒症的临床评价

Clinical evaluation of linezolid in the treatment of sepsis in ICU

关键词:  利奈唑胺  脓毒症  有效性

Key words:  linezotid  sepsis  efficacy

摘要:

[目的] 评价利奈唑胺治疗ICU脓毒症的疗效与安全性。〖ＨＴH〗[方法] 收集接受利奈唑胺治疗60 例脓毒症患者的临床资料。观察临床疗效、不良反应及病原学监测情况。[结果] 60 例脓毒症患者治疗总有效率为76.67%(46／60)，耐甲氧西林金黄色葡萄球菌感染患者有效率75%(24／32)，表皮葡萄球菌感染患者有效率83.33%(10／12)，屎肠球菌感染患者有效率71.43%（10／14)，粪肠球菌感染患者有效率83.33%(5／6)，人葡萄球菌感染患者有效率100%(4／4)，耳葡萄球菌感染患者有效率100% (2／2)，微球菌属感染患者有效率100%(2／2)，治疗过程中不良反应发生率为18.33%。[结论] 利奈唑胺是治疗ICU重症感染有效、安全的药物。

Abstract:

[Objective] To evaluate the efficacy and safety of linezolid in the treatment of sepsis in ICU. [Methods] A retrospective analysis of the clinical data was conducted for 60 patients with sepsis and treated with linezolid in emergency intensive care unit (EICU). [Results] The results showed the total efficacy rate was 76.67% (46／60), 75% (24／32) among the patients with the infection of Meticillin-resistant Staphylococcus aureus (MRSA), 83.33% (10／12) among the patients with the infection of Staphylococcus epidermidis, 71.43% (10／14) among the patients with the infection of Enterococcus faecium, 83.33% (5／6) among the patients with the infection of Enterococcus faecalis, 100% (4/4) among the patients with the infection of Staphylococcus hominis, 100% (2/2) among the patients with the infection of Staphylococcus auricularis, 100% (2/2) among the patients with the infection of Micrococcus, the drug-related side effect rate was 18.33%. [Conclusion] Linezolid is likely to be an effective and safe treatment for severe infections in ICU.